Final results of 2-dose fractionation of 177mLu-J591 for progressive metastatic castration-resistant prostate cancer mCRPC).

被引：8
|
作者：
Tagawa, Scott T.
Batra, Jaspreet
Vallabhajosula, Shankar
Jhanwar, Yuliya
Christos, Paul J.
Emmerich, Lauren
Karir, Beerinder S.
Karpenko, Irene
Lam, Linda
Febles, Victor R. A.
Molina, Ana M.
Beltran, Himisha
Goldsmith, Stanley J.
Bander, Neil Harrison
Nanus, David M.
机构：
[1] Weill Cornell Med, New York, NY USA
[2] Weill Cornell Med Coll, New York, NY USA
[3] Weill Cornell Med, New York Presbyterian Hosp, New York, NY USA
[4] New York Presbyterian Hosp Cornell, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.5022
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5022
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Phase I/II study of 225Ac-J591 plus 177Lu-PSMA-I&T for progressive metastatic castration-resistant prostate cancer
    Nauseef, Jones T.
    Osborne, Joseph
    Gregos, Peter
    Thomas, Charlene
    Bissassar, Mahelia
    Singh, Sharon
    Patel, Amie
    Tan, Angela
    Naiz, Muhammad Obaid
    Zuloaga, Juana Martinez
    Chamberlain, Tessa
    Earle, Kara
    Wunder, Rebecca
    Nagar, Himanshu
    Molina, Ana M.
    Sternberg, Cora N.
    Nanus, David M.
    Bander, Neil Harrison
    Tagawa, Scott T.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [32] ADRB2 expression in progressive metastatic castration-resistant prostate cancer
    Kwon, Daniel
    Zhang, Li
    Foye, Adam
    Chen, William S.
    Feng, Felix Y.
    Bailey, Adina
    Huang, Jiaoti
    Quigley, David A.
    Stuart, Josh
    Friedl, Verena
    Weinstein, Alana
    Beer, Tomasz M.
    Alumkal, Joshi J.
    Rettig, Matthew
    Gleave, Martin
    Lara, Primo
    Li, Patricia
    Lui, Austin
    Small, Eric Jay
    Aggarwal, Rahul Raj
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [33] Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC)
    Sonpavde, Guru
    Wang, Christopher G.
    Galsky, Matthew D.
    Oh, William K.
    Armstrong, Andrew J.
    BJU INTERNATIONAL, 2015, 116 (01) : 17 - 29
  • [34] Phase II Study with metastatic castration-resistant Prostate Cancer (mCRPC) Patients
    Rexer, H.
    Graefen, M.
    UROLOGE, 2017, 56 (11): : 1468 - 1470
  • [35] INTERMITTENT (RECHALLENGE) CHEMOTHERAPY WITH DOCETAXEL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
    Bracarda, Sergio
    Rossi, Marta
    Hamzaj, Alketa
    De Angelis, Verena
    De Simone, Valeria
    Caserta, Claudia
    Crino, Lucio
    ANNALS OF ONCOLOGY, 2009, 20
  • [36] Sequencing in metastatic castration-resistant prostate cancer (mCRPC): Updated results of the FLAC International Database.
    Delanoy, Nicolas
    Angelergues, Antoine
    Efstathiou, Eleni
    Gyftaki, Revekka
    Wysocki, Piotr Jan
    Lainez, Nuria
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [37] Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC).
    Clement-Zhao, Alice
    Auvray, Marie
    Verret, Benjamin
    Vano, Yann Alexandre
    Angelergues, Antoine
    Oudard, Stephane
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [38] Phase I dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)
    Tagawa, S. T.
    Vallabhajosula, S.
    Jhanwar, Y.
    Hackett, A.
    Oromendia, C.
    Naiz, M. J.
    Goldsmith, S. J.
    Nanus, D. M.
    Beltran, H.
    Molina, A. M.
    Faltas, B.
    Sreekumar, J.
    Babich, J.
    Ballman, K.
    Bander, N. H.
    ANNALS OF ONCOLOGY, 2018, 29
  • [39] Preliminary results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)
    Tagawa, S. T.
    Osborne, J. R.
    Hackett, A.
    Niaz, M. J.
    Cooley, V.
    Christos, P.
    Vlachostergios, P. J.
    Thomas, C.
    Gracey, L.
    Beltran, H.
    Molina, A. M.
    Nanus, D. M.
    Babich, J.
    Vallabhajosula, S.
    Sartor, O.
    Ballman, K.
    Bander, N. H.
    ANNALS OF ONCOLOGY, 2019, 30
  • [40] Phase I dose-escalation study of PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Osborne, Joseph
    Fernandez, Escarleth
    Thomas, Charlene
    Niaz, Muhammad Junaid
    Ciriaco, Amy
    Vallabhajosula, Shankar
    Vlachostergios, Panagiotis J.
    Molina, Ana M.
    Sternberg, Cora N.
    Singh, Sharon
    Babich, John
    Nanus, David M.
    Ballman, Karla, V
    Bander, Neil Harrison
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345